237 related articles for article (PubMed ID: 16971971)
1. Molecule of the month. Vorinostat.
Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971
[No Abstract] [Full Text] [Related]
2. Vorinostat.
Grant S; Easley C; Kirkpatrick P
Nat Rev Drug Discov; 2007 Jan; 6(1):21-2. PubMed ID: 17269160
[No Abstract] [Full Text] [Related]
3. Histone deacetylase inhibitors in cancer therapy.
Fouladi M
Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
[No Abstract] [Full Text] [Related]
4. Histone deacetylase inhibitors: overview and perspectives.
Dokmanovic M; Clarke C; Marks PA
Mol Cancer Res; 2007 Oct; 5(10):981-9. PubMed ID: 17951399
[TBL] [Abstract][Full Text] [Related]
5. HDAC2 deficiency and histone acetylation.
Ree AH; Folkvord S; Flatmark K
Nat Genet; 2008 Jul; 40(7):812-3; author reply 813. PubMed ID: 18583969
[No Abstract] [Full Text] [Related]
6. Vorinostat (Zolinza) for cutaneous T-Cell lymphoma.
Med Lett Drugs Ther; 2007 Mar; 49(1256):23-4. PubMed ID: 17351559
[No Abstract] [Full Text] [Related]
7. Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications.
Thaler F
Pharm Pat Anal; 2012 Mar; 1(1):75-90. PubMed ID: 24236715
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of histone deacetylase are potentially effective anticancer agents.
Marks PA; Rifkind RA; Richon VM; Breslow R
Clin Cancer Res; 2001 Apr; 7(4):759-60. PubMed ID: 11309319
[No Abstract] [Full Text] [Related]
9. Vorinostat approved for rare lymphoma.
Thompson CA
Am J Health Syst Pharm; 2006 Nov; 63(22):2168. PubMed ID: 17090730
[No Abstract] [Full Text] [Related]
10. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
11. HDAC inhibitors: magic bullets, dirty drugs or just another targeted therapy.
Witt O; Lindemann R
Cancer Lett; 2009 Aug; 280(2):123-4. PubMed ID: 19303208
[No Abstract] [Full Text] [Related]
12. Development of vorinostat: current applications and future perspectives for cancer therapy.
Richon VM; Garcia-Vargas J; Hardwick JS
Cancer Lett; 2009 Aug; 280(2):201-10. PubMed ID: 19181442
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.
Richon VM; Zhou X; Rifkind RA; Marks PA
Blood Cells Mol Dis; 2001; 27(1):260-4. PubMed ID: 11358386
[No Abstract] [Full Text] [Related]
14. HDAC inhibitors overcome first hurdle.
Garber K
Nat Biotechnol; 2007 Jan; 25(1):17-9. PubMed ID: 17211382
[No Abstract] [Full Text] [Related]
15. [Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors].
Zirlik K; Nashan D; Veelken H
Pharm Unserer Zeit; 2010 May; 39(3):190-6. PubMed ID: 20425773
[No Abstract] [Full Text] [Related]
16. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors: biology and mechanism of action.
Mehnert JM; Kelly WK
Cancer J; 2007; 13(1):23-9. PubMed ID: 17464243
[TBL] [Abstract][Full Text] [Related]
18. HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines.
Flis S; Gnyszka A; Spławiński J
Biochem Biophys Res Commun; 2009 Sep; 387(2):336-41. PubMed ID: 19596269
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors: novel agents in cancer treatment.
Glass E; Viale PH
Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors as anti-neoplastic agents.
Batty N; Malouf GG; Issa JP
Cancer Lett; 2009 Aug; 280(2):192-200. PubMed ID: 19345475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
